Investors today commonly associate the obesity market with three main players: Orexigen (NASDAQ: OREX), which is still developing its drugs Contrave and Empatic, VIVUS (VVUS +0.00%), which recently launched its therapeutic Qsymia, and Arena Pharmaceuticals (ARNA +0.00%), which gained FDA approval for Belviq back in June and is poised to launch the drug with its partner Eisai.
Interestingly, a recent study showed that one of Eisai's epilepsy drugs, called Zonegran, may also be a potential weight-loss medicine. In the following video, health-care analysts Max Macaluso and David Williamson analyze this story and identify some things Arena investors should watch in both the near and long term.
